Press Releases - Daiichi Sankyo US
4 days ago · Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the U.S. for the …
Enhertu approved in the US as first HER2-directed therapy for …
3 days ago · AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone …
ENHERTU® Approved in the U.S. as the First HER2 ... - Daiichi Sankyo
Aug 5, 2022 · Following approval in the U.S., an amount of $200 million is due from AstraZeneca to Daiichi Sankyo as a milestone payment for an indication for ENHERTU in patients with …
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the …
4 days ago · AstraZeneca and Daiichi Sankyo’s ENHERTU ® (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with unresectable or …
ENHERTU - Daiichi Sankyo
Jan 18, 2021 · Designed using Daiichi Sankyo’s proprietary DXd ADC technology, ENHERTU is the lead ADC in the oncology portfolio of Daiichi Sankyo and the most advanced program in …
Enhertu approved in the US as first tumour-agnostic HER2 …
Apr 6, 2024 · AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2 …
ENHERTU now has five approved indications with the latest in HER2 ...
Apr 5, 2024 · ENHERTU is a specifically engineered HER2-directed antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by …
Press Releases - Daiichi Sankyo US
ENHERTU is a specifically engineered HER2 directed antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and …
Aug 19, 2024 · ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and …
Enhertu approved in the EU as the first HER2-directed therapy for ...
Oct 23, 2023 · AstraZeneca and Daiichi Sankyo’s (trastuzumab deruxtecan) has been approved in the European Union (EU) as monotherapy for the treatment of adult patients with advanced …
- Some results have been removed